메뉴 건너뛰기




Volumn 3, Issue 122, 2007, Pages 1876-1883

Glitazones and congestive heart failure: Update on PROactive, ADOPT, DREAM and RECORD clinical trials;Glitazones et insuffisance cardiaque: Résultats des études PROactive, ADOPT, DREAM et RECORD

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; METFORMIN; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

EID: 34548756679     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (9)

References (30)
  • 1
    • 33748946748 scopus 로고    scopus 로고
    • * De Flines J, Scheen AJ. Diabète sucré et décompensation cardiaque: spécificités é tiopathogéniques et thérapeutiques. Rev Med Suisse 2006;2:1893-900.
    • * De Flines J, Scheen AJ. Diabète sucré et décompensation cardiaque: spécificités é tiopathogéniques et thérapeutiques. Rev Med Suisse 2006;2:1893-900.
  • 2
    • 10744221639 scopus 로고    scopus 로고
    • ** Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-63.
    • ** Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-63.
  • 3
    • 0037453063 scopus 로고    scopus 로고
    • Glitazones and heart failure: Critical appraisal for the clinician
    • Wang CH, Weisel RD, Liu PP, Fedak PW, Verma S. Glitazones and heart failure: Critical appraisal for the clinician. Circulation 2003;107:1350-4.
    • (2003) Circulation , vol.107 , pp. 1350-1354
    • Wang, C.H.1    Weisel, R.D.2    Liu, P.P.3    Fedak, P.W.4    Verma, S.5
  • 4
    • 19244365650 scopus 로고    scopus 로고
    • Thiazolidinediones
    • Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18.
    • (2004) N Engl J Med , vol.351 , pp. 1106-1118
    • Yki-Järvinen, H.1
  • 5
    • 34247122261 scopus 로고    scopus 로고
    • Fluid retention with thiazolidinediones. Does the mechanism influence the outcome ?
    • Lindenfeld J, Masoudi FA. Fluid retention with thiazolidinediones. Does the mechanism influence the outcome ? J Am Coll Cardiol 2007;49:1705-7.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 1705-1707
    • Lindenfeld, J.1    Masoudi, F.A.2
  • 6
    • 26244453309 scopus 로고    scopus 로고
    • ** Dormandy J, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366:1279-89.
    • ** Dormandy J, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005;366:1279-89.
  • 7
    • 33845405222 scopus 로고    scopus 로고
    • ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med
    • ** Kahn SE, Haffner SM, Heise MA, et al for the
    • ** Kahn SE, Haffner SM, Heise MA, et al for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.
    • (2006) , vol.355 , pp. 2427-2443
  • 8
    • 33748748206 scopus 로고    scopus 로고
    • Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial
    • ** The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trials Investigators
    • ** The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trials Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006;368:1096-105.
    • (2006) Lancet , vol.368 , pp. 1096-1105
  • 9
    • 26244444319 scopus 로고    scopus 로고
    • The PROactive study: Some answers, many questions
    • Yki-Járvinen H. The PROactive study: Some answers, many questions. Lancet 2005;366:1241-2.
    • (2005) Lancet , vol.366 , pp. 1241-1242
    • Yki-Járvinen, H.1
  • 10
    • 33846222754 scopus 로고    scopus 로고
    • Adjudication of serious heart failure in patients from PROactive
    • Ryden L, Thrainsdottir I, Swedberg K. Adjudication of serious heart failure in patients from PROactive. Lancet 2007;369:189-90.
    • (2007) Lancet , vol.369 , pp. 189-190
    • Ryden, L.1    Thrainsdottir, I.2    Swedberg, K.3
  • 11
    • 33847675510 scopus 로고    scopus 로고
    • on behalf of the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction
    • Erdmann E, Dormandy JA, Charbonnel B et al, on behalf of the PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. J Am Coll Cardiol 2007;49:1772-80.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 1772-1780
    • Erdmann, E.1    Dormandy, J.A.2    Charbonnel, B.3
  • 12
    • 33947539408 scopus 로고    scopus 로고
    • PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)
    • Wilcox R, Bousser MG, Betteridge DJ, et al. PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007;38: 865-73.
    • (2007) Stroke , vol.38 , pp. 865-873
    • Wilcox, R.1    Bousser, M.G.2    Betteridge, D.J.3
  • 13
    • 0242332284 scopus 로고    scopus 로고
    • Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes. A retrospective cohort study
    • Delea TE, Edetsberg JS, Hagiwara M, Oster G, Philips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes. A retrospective cohort study. Diabetes Care 2003;26:2983-9.
    • (2003) Diabetes Care , vol.26 , pp. 2983-2989
    • Delea, T.E.1    Edetsberg, J.S.2    Hagiwara, M.3    Oster, G.4    Philips, L.S.5
  • 14
    • 21544465051 scopus 로고    scopus 로고
    • Insulin-sensitizing anti hyperglycemic drugs and mortality after acute myocardial infarction: Insights from the National Heart Care Project
    • Inzucchi SE, Masoudi FA, Wang Y, et al. Insulin-sensitizing anti hyperglycemic drugs and mortality after acute myocardial infarction: Insights from the National Heart Care Project. Diabetes Care 2005;28:1680-9.
    • (2005) Diabetes Care , vol.28 , pp. 1680-1689
    • Inzucchi, S.E.1    Masoudi, F.A.2    Wang, Y.3
  • 15
    • 22644438570 scopus 로고    scopus 로고
    • Pioglitazone initiation and subsequent hospitalization for congestive heart failure
    • Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005;22:986-93.
    • (2005) Diabet Med , vol.22 , pp. 986-993
    • Karter, A.J.1    Ahmed, A.T.2    Liu, J.3    Moffet, H.H.4    Parker, M.M.5
  • 16
    • 13444272949 scopus 로고    scopus 로고
    • Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study
    • Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study. Circulation 2005;11:583-90.
    • (2005) Circulation , vol.11 , pp. 583-590
    • Masoudi, F.A.1    Inzucchi, S.E.2    Wang, Y.3
  • 17
    • 33746588255 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
    • Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72.
    • (2006) Diabetes Care , vol.29 , pp. 1963-1972
    • Nathan, D.M.1    Buse, J.B.2    Davidson, M.B.3
  • 19
    • 33947134267 scopus 로고    scopus 로고
    • * Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: A meta-analysis. Diabetes Res Clin Pract 2006;76:279-89.
    • * Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: A meta-analysis. Diabetes Res Clin Pract 2006;76:279-89.
  • 20
    • 34548776617 scopus 로고    scopus 로고
    • De Flines J, Scheen AJ. Pioglitazone, oedema and congestive heart failure: A meta-analysis of randomised controlled trials (abstract). Diabetologia 2007;50 (Suppl. 1): in press.
    • De Flines J, Scheen AJ. Pioglitazone, oedema and congestive heart failure: A meta-analysis of randomised controlled trials (abstract). Diabetologia 2007;50 (Suppl. 1): in press.
  • 21
    • 23844472901 scopus 로고    scopus 로고
    • Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption
    • Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861-6.
    • (2005) Nat Med , vol.11 , pp. 861-866
    • Guan, Y.1    Hao, C.2    Cha, D.R.3
  • 22
    • 4944262294 scopus 로고    scopus 로고
    • Combined thiazolidinedione-insulin therapy. Should we be concerned about safety?
    • Scheen AJ. Combined thiazolidinedione-insulin therapy. Should we be concerned about safety? Drug Safety 2004;27:841-56.
    • (2004) Drug Safety , vol.27 , pp. 841-856
    • Scheen, A.J.1
  • 23
    • 0037393015 scopus 로고    scopus 로고
    • Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure
    • Tang WHW, Francis GS, Hoogwerf BJ, Young JB. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003;41:1394-8.
    • (2003) J Am Coll Cardiol , vol.41 , pp. 1394-1398
    • Tang, W.H.W.1    Francis, G.S.2    Hoogwerf, B.J.3    Young, J.B.4
  • 24
    • 7044253431 scopus 로고    scopus 로고
    • A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
    • Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104.
    • (2004) Arch Intern Med , vol.164 , pp. 2097-2104
    • Chiquette, E.1    Ramirez, G.2    DeFronzo, R.3
  • 25
    • 33846657175 scopus 로고    scopus 로고
    • Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: A meta-analysis
    • Riche DM, Valderrama R, Henyan NN. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: A meta-analysis. Diabetes Care 2007;30:384-8.
    • (2007) Diabetes Care , vol.30 , pp. 384-388
    • Riche, D.M.1    Valderrama, R.2    Henyan, N.N.3
  • 26
    • 34250212715 scopus 로고    scopus 로고
    • * Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
    • * Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
  • 27
    • 34250178250 scopus 로고    scopus 로고
    • Rosiglitazone and cardiovascular risk
    • Psaty BM, Furberg CD. Editorial. Rosiglitazone and cardiovascular risk. N Engl J Med 2007;356:2522-4.
    • (2007) N Engl J Med , vol.356 , pp. 2522-2524
    • Psaty, B.M.1    Furberg, C.D.2    Editorial3
  • 28
    • 24944569269 scopus 로고    scopus 로고
    • Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol
    • Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol. Diabetologia 2005;48:1726-35.
    • (2005) Diabetologia , vol.48 , pp. 1726-1735
    • Home, P.D.1    Pocock, S.J.2    Beck-Nielsen, H.3
  • 29
    • 34250865768 scopus 로고    scopus 로고
    • * Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007;357:28-38.
    • * Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007;357:28-38.
  • 30
    • 34250826679 scopus 로고    scopus 로고
    • Rosiglitazone and cardiotoxicity - Weighing the evidence
    • Nathan DM. Rosiglitazone and cardiotoxicity - Weighing the evidence. N Engl J Med 2007;357:64-6.
    • (2007) N Engl J Med , vol.357 , pp. 64-66
    • Nathan, D.M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.